Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme Authors: Chin Hang Yiu, Bella D Ianni, Richard O Day, Jacques Raubenheimer, Christine Y Lu Published: 2026 ABSTRACT AbstractBiologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public expenditure impact of TNF inhibitor biosimilars under regulated pricing systems has not been comprehensively quantified. We conducted a retrospective, population‐level expenditure analysis using publicly available PBS Item Reports data from 2015 to 2025 to estimate PBS cost savings associated with the listing of adalimumab, etanercept, and infliximab biosimilars for inflammatory arthritis. Counterfactual scenarios were constructed to estimate expected expenditure in the absence of biosimilar entry, explicitly accounting for key PBS pricing mechanisms, including mandatory price reductions and price‐disclosure cycles. Biosimilar listing was associated with cumulative PBS savings of AU$562.3 million over the study period. Etanercept biosimilar generated the largest absolute savings (AU$341.5 million; 23.7% reduction), whereas adalimumab biosimilars generated smaller relative savings (AU$195.3 million; 9.4% reduction), reflecting delayed biosimilar entry despite high utilization. Most savings accrued in rheumatoid arthritis, followed by ankylosing spondylitis and psoriatic arthritis. In conclusion, TNF inhibitor biosimilars were associated with substantial and sustained reductions in public medicine expenditure in Australia. The magnitude of savings varied markedly by molecule and was jointly determined by the timing of biosimilar entry and statutory pricing mechanisms, illustrating how regulated reimbursement systems shape realized biosimilar value. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Tumor necrosis factor (TNF) inhibitors are among the most widely prescribed and highest‐cost biologic therapies worldwide. Biosimilars are known to reduce medicine prices; however, evidence quantifying cumulative, system‐level cost savings from TNF inhibitor biosimilars in Australia is limited, particularly when considering Australia's unique Pharmaceutical Benefits Scheme (PBS) pricing framework. WHAT QUESTION DID THIS STUDY ADDRESS? This study estimated PBS expenditure savings associated with the listing of adalimumab, etanercept, and infliximab biosimilars for inflammatory arthritis in Australia between 2015 and 2025. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? Using population‐level PBS data and counterfactual pricing scenarios, this study demonstrates that TNF inhibitor biosimilars generated over AU$562 million in cumulative savings. The magnitude of savings varied substantially by molecule and indication and was strongly influenced by the interaction between biosimilar entry timing and statutory PBS pricing mechanisms. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? Our findings highlight timely biosimilar availability as a key, modifiable policy lever for maximizing public health system savings. They support optimizing the timing of biosimilar market entry and reimbursement listing to improve the sustainability, affordability, and equitable access to biologic therapies. Global pharmaceutical expenditures continue to rise, with total medicine spending projected to grow by 3–6% annually. 1 Biologic therapies account for a disproportionate share of this growth in high‐income countries, including across Europe, North America, and Australia. 2 , 3 In rheumatology, biologic disease‐modifying antirheumatic drugs (bDMARDs) are central to the management of chronic inflammatory diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA). 4 Although these therapies have transformed clinical outcomes by suppressing inflammation and preventing irreversible joint damage, 5 their high cost poses ongoing challenges for affordability, equitable access, and long‐term health system sustainability. Biosimilars, biologic products that are highly similar to originator biologics, offer a potential strategy to mitigate rising biologic expenditure without compromising patient outcomes. 6 Regulatory approval requires comparability testing to demonstrate no clinically meaningful differences in efficacy, safety, or immunogenicity. Evidence from randomized controlled trials and meta‐analyses consistently supports therapeutic equivalence between TNF inhibitor biosimilars and their reference products, 7 , 8 with real‐world studies further demonstrating comparable effectiveness and treatment persistence following biosimilar initiation or switching. 9 , 10 , 11 The extent to which biosimilars generate cost savings, however, depends not only on their availability but also on the pricing and reimbursement frameworks governing their adoption. In Australia, biosimilar uptake is promoted through the Pharmaceutical Benefits Scheme (PBS) using statutory pricing mechanisms rather than mandatory nonmedical switching. Under this framework, the first PBS listing of a biosimilar triggers a mandatory price reduction for the reference biologic, with both the originator and biosimilar listed at the same reduced benchmark price. Subsequent price adjustments occur through price‐disclosure cycles and additional statutory reductions. 12 These mechanisms differ substantially from those used in jurisdictions such as the United States (US) and parts of Europe, which rely on tendering, confidential rebates, or mandatory switching policies where biosimilar pricing is more strongly influenced by market competition. 13 , 14 This positions Australia as a distinct policy setting for evaluating biosimilar‐associated savings. Despite more than a decade of TNF inhibitor biosimilar availability in Australia, the aggregate public expenditure impact of these products under the PBS has not been comprehensively evaluated. Understanding the magnitude and drivers of biosimilar‐associated savings is particularly important given PBS's unique pricing architecture and its implications for future biologic and biosimilar funding decisions. This study therefore aimed to estimate PBS cost savings associated with TNF inhibitor biosimilars used in inflammatory arthritis from 2015 to 2025, explicitly accounting for key PBS pricing mechanisms. By explicitly modeling PBS pricing mechanisms, this study isolates the contribution of regulatory price dynamics to realized biosimilar savings, providing generalizable insights into how reimbursement design shapes the economic value of biosimilar entry across health systems. METHODS This study was designed as a retrospective policy evaluation of biosimilar‐associated pricing interventions within Australia's PBS, assessing their impact on public medicine expenditure rather than on individual‐level prescribing or utilization. We examined the use of three TNF inhibitors: adalimumab, etanercept, and infliximab for the treatment of RA, AS, PsA, and JIA in Australia between January 1, 2015 and December 31, 2025. The PBS listing dates for each biosimilar product are summarized in Table 1 . Over the study period (2015–2025), 12 biosimilar brands were added to the PBS: seven for adalimumab, three for etanercept, and two for infliximab (Table 1 ). As the analysis used publicly available, aggregated data, ethics approval from a Human Research Ethics Committee was not required. Table 1PBS listing dates of biosimilars used in inflammatory arthritisDrug (originator brand)Biosimilar branda PBS listing datePBS‐listed therapeutic indicationsNumber of available biosimilar brands as of December 31, 2025Adalimumab (Humira)Amgevita, Hadlima, Hyrimoz, Idacio2021‐Apr‐01RA, AS, PsA, JIA7Yuflyma2023‐Mar‐01Adalicip2024‐Jan‐01Abrilada2024‐Aug‐01Etanercept (Enbrel)Brenzys2017‐Apr‐01RA, AS, PsA, JIA3Erelzi, Nepexto2025‐Jul‐01Infliximab (Remicade)Inflectra2015‐Dec‐01RA, AS, PsA2Renflexis2017‐Aug‐01AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; PBS, Pharmaceutical Benefits Scheme; PsA, psoriatic arthritis; RA, rheumatoid arthritis. a Available biosimilar brands as of December 31, 2025. PBS listing dates of biosimilars used in inflammatory arthritis AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; PBS, Pharmaceutical Benefits Scheme; PsA, psoriatic arthritis; RA, rheumatoid arthritis. Available biosimilar brands as of December 31, 2025. Study setting In Australia, the PBS, a core component of the national Medicare program, provides subsidized access to prescription medicines for all Australian citizens and permanent residents. 15 PBS reimbursement prices are published in the PBS Schedule and are adjusted over time in response to statutory policy settings and market dynamics. Several PBS pricing mechanisms are therefore relevant to this study. PBS pricing policy distinguishes between single‐brand (F1) and multi‐brand (F2) formularies. Medicines are generally listed on the F1 formulary when only a single brand is available. The entry of competing brands, including biosimilars, typically triggers a transition to the F2 formulary, where unit prices are adjusted via Price Disclosure (PD) to maintain price competitiveness. 16 , 17 For medicines remaining on the F1 formulary, the Anniversary Price Reduction (APR) policy, introduced in 2016, mandates price reductions at the 5‐, 10‐, and 15‐year anniversaries of PBS listing. 16 , 18 Upon transition to F2, further anniversary reductions no longer apply. Specifically for biologic medicines, the PBS listing of the first biosimilar triggers a mandatory statutory price reduction (SPR) for the reference biologic, with the biosimilar listed at the same reduced benchmark price to maintain price parity across brands. 12 In April 2023, Section 99ACN of the National Health Act 1953 introduced a one‐off statutory “catch‐up” price reduction for eligible medicines that had been PBS‐listed for at least 15 years and had not previously undergone PD, up to a legislated maximum of 36.82% ( Supplementary Note for additional information). 19 Data source and collection PBS dispensing data are generated each time a PBS‐listed medicine is supplied by an approved pharmacy. Each record is identified by an item code specifying the medicine's generic name, strength, dosage form, and route of administration. 20 For biologic therapies, PBS item codes are also indication‐specific, allowing prescribing volumes and associated costs to be disaggregated by clinical indication (RA, AS, PsA, JIA). For each TNF inhibitor and indication, all relevant PBS item codes were identified through a comprehensive review of PBS Schedule listings across the study period (Tables S1 – S3 ). Where multiple item codes existed for a given drug‐indication combination (i.e., differing strengths or formulations), prescription volumes were summed to capture total utilization. PBS dispensing data include medicines supplied through community pharmacies and public hospital pharmacies. In New South Wales, PBS claims are restricted to Section (Highly Specialized Drugs); as all study drugs are supplied under Section 100 arrangements, data completeness was unaffected. Monthly utilization data were obtained from PBS Item Reports (https://medicarestatistics.humanservices.gov.au/statistics/pbs_item.html). Utilization was quantified as the number of “services,” with each service representing a single PBS prescription. For example, one service of etanercept 50 mg represents a standard 1‐month treatment supply (four doses). Drug prices were derived from Approved Ex‐Manufacturer Price (AEMP) using PBS monthly price files (https://www.pbs.gov.au/info/industry/pricing/ex‐manufacturer‐price). AEMP were extracted for all relevant formulations and strengths across the study period. The unit price of a drug was consistent across indications. Data extraction and verification were independently performed by two investigators (C.H.Y and B.D.I) using Microsoft Excel. Actual scenario The originator biologics adalimumab, etanercept, and infliximab were first listed on the PBS between 2003 and 2004. 21 In the observed (actual) scenario, unit prices changed over time in line with the PBS pricing mechanisms described above. For each reference biologic, the first biosimilar PBS listing triggered an SPR, with originator and biosimilar products listed at the same reduced benchmark price. For example, the PBS listing of the etanercept biosimilar Brenzys in April 2017 was associated with a 40% reduction in the PBS‐listed unit price (Tables S4 and S5 ). Scheduled APRs applied while products remained on the F1 formulary. Adalimumab underwent all three anniversary reductions: April 2016 (5‐year), June 2018 (10‐year), and April 2020 (15‐year) prior to its first biosimilar PBS listing on 1 April 2021. 18 Etanercept received its 5‐year reduction in April 2016 before transitioning to the F2 formulary at biosimilar listing in April 2017. Infliximab transitioned to F2 in December 2015 following early biosimilar listing, prior to implementation of the APR policy. Following transition to the F2 formulary, PD drove further reductions for infliximab. From 2018 onwards, the PBS‐listed unit price of infliximab 100 mg underwent four successive PD‐driven reductions, ranging from ~ 11–28% per adjustment (Table S6 ). No PD‐related reductions were observed for adalimumab or etanercept during the study period. Consequently, both medicines were subject to the April 2023 catch‐up SPR, ranging from 6.91% to 20.83% (Tables S4 , S5 , S8 , S9 ). Actual monthly PBS expenditure was calculated by multiplying observed monthly dispensing volumes by the applicable AEMP at the time of dispensing, capturing all statutory, anniversary‐related, and PD‐driven price adjustments, reflecting real‐world expenditure trends across the study period. Counterfactual (hypothetical) scenario In the counterfactual scenario, biosimilar versions of adalimumab, etanercept, and infliximab were assumed not to enter the PBS market. Observed monthly prescription volumes were used directly and applied entirely to the originator products in the absence of biosimilar entry, without adjustment to total utilization. This approach isolates the impact of biosimilar‐related pricing changes from observed utilization patterns, consistent with evaluations of pharmaceutical pricing policy. Under this assumption, unit prices for each originator biologic were fixed at the level observed immediately prior to biosimilar PBS listing. Biosimilar‐triggered SPRs and all PD‐related reductions were excluded. All medicines were assumed to remain on the F1 formulary for the study period and were therefore eligible only for scheduled APRs. APRs were applied according to standard PBS F1 formulary rules (5‐, 10‐, and 15‐year anniversary reductions) based on each biologic's initial PBS listing date. As adalimumab, etanercept, and infliximab were all PBS‐listed between 2003 and 2004, this resulted in the same APR schedule across all three agents: April 2016 (5‐year), June 2018 (10‐year), and April 2020 (15 year). In the counterfactual scenario, this rule‐based schedule was retained for each biologic as a deterministic application of PBS statutory pricing rules under unchanged listing conditions. In addition, a one‐off statutory “catch‐up” price reduction was applied in the absence of PD. Under the counterfactual assumptions, the magnitude of this reduction was 22.2% for all three drugs (Tables S4 – S9 ; Supplementary Note for additional information). Counterfactual expenditure was calculated as the product of observed dispensing volumes and hypothetical unit prices (no biosimilar listing). Expenditure analysis For each reference biologic (adalimumab, etanercept, infliximab), all corresponding biosimilar products were grouped together. The earliest PBS listing date of any biosimilar for a given agent defined the timing of biosimilar listing, irrespective of the number or identity of subsequent biosimilar brands. Cumulative cost savings were estimated as the difference between counterfactual and actual PBS expenditure for each drug, aggregated from the month of biosimilar listing through December 2025. All costs are reported in Australian dollars (AUD). Relative cost savings were calculated as the percentage difference between counterfactual and actual expenditure. For indication‐level analyses, prescription volumes were extracted using indication‐specific PBS item codes, enabling disaggregation by clinical indication (RA, AS, PsA, JIA). Each drug‐indication combination was analyzed independently based on its corresponding item codes; dispensing volumes were not redistributed across indications. Detailed derivation of actual and counterfactual unit prices is provided in the Supplementary File (Tables S4 – S9 ; Figures S1 – S3 ). RESULTS Overall expenditure savings The PBS listing of biosimilars for adalimumab, etanercept, and infliximab was associated with cumulative cost saving of AU$562,316,855 over the study period, corresponding to a 15.7% reduction in PBS expenditure attributable to biosimilar‐associated pricing changes (Table 2 ). Total PBS expenditure during post‐biosimilar PBS listing periods was AU$3,020,520,622 (actual), compared with AU$3,582,837,477 under the counterfactual scenario without biosimilar listing. Table 2Total estimated savings within each drugActual PBS spendingCounterfactual PBS spendingTotal estimated savingTotal estimated saving, %Adalimumab (from 2021‐Apr)$1,873,055,287$2,068,346,297$195,291,0109.4Etanercept (from 2017‐Apr)$1,100,963,015$1,442,490,072$341,527,05723.7Infliximab (from 2015‐Dec)$46,502,320$72,001,108$25,498,78835.4Total (Adalimumab + Etanercept + Infliximab)$3,020,520,622$3,582,837,477$562,316,85515.7The actual scenario reflects observed PBS dispensing volumes and unit prices over time, incorporating the effects of biosimilar listing, mandatory price reductions, and price‐disclosure mechanisms. The counterfactual scenario models a hypothetical setting in which biosimilars were not listed on the PBS, with originator prices remaining at pre‐biosimilar levels, subject only to scheduled anniversary price reductions. The savings estimate represents the difference between counterfactual and actual PBS expenditure over the post‐biosimilar period, quantifying the net financial impact of biosimilar market entry and associated pricing policies. AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; PBS, Pharmaceutical Benefits Scheme; PsA, psoriatic arthritis; RA, rheumatoid arthritis. Total estimated savings within each drug The actual scenario reflects observed PBS dispensing volumes and unit prices over time, incorporating the effects of biosimilar listing, mandatory price reductions, and price‐disclosure mechanisms. The counterfactual scenario models a hypothetical setting in which biosimilars were not listed on the PBS, with originator prices remaining at pre‐biosimilar levels, subject only to scheduled anniversary price reductions. The savings estimate represents the difference between counterfactual and actual PBS expenditure over the post‐biosimilar period, quantifying the net financial impact of biosimilar market entry and associated pricing policies. AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; PBS, Pharmaceutical Benefits Scheme; PsA, psoriatic arthritis; RA, rheumatoid arthritis. Savings by drug Etanercept accounted for the largest proportion of absolute savings, with AU$341,527,057 saved, representing a 23.7% reduction relative to counterfactual expenditure (Figure 1 ). Early PBS listing of an etanercept biosimilar in April 2017 allowed a longer period of price competition and successive price reductions, resulting in greater cumulative savings. Actual vs. counterfactual spending for etanercept. Adalimumab generated AU$195,291,010 in savings (9.4% reduction; Figure 2 ). Despite the highest prescription volumes and the largest number of biosimilar brands listed during the study period (Table S10 ), savings were comparatively modest. This reflected delayed PBS listing of adalimumab biosimilars in April 2021, nearly 6 years after infliximab and 4 years after etanercept, and the later timing of the first PD in April 2024, which reduced the duration of exposure to price reductions. Actual vs. Counterfactual Spending for adalimumab. Infliximab produced the smallest absolute savings (AU$25,498,788) but the greatest relative reduction in expenditure (35.4%; Figure 3 ). This reflected earlier biosimilar PBS listing in December 2015 and longer exposure to successive PD‐driven reductions (four rounds of PD). Actual vs. Counterfactual Spending for infliximab. Savings by indication When stratified by clinical indications (Table 3 ), RA accounted for the largest share of cumulative savings (AU$306,870,817; 54.6% of total savings across all agents). This was followed by AS (AU$124,577,892; 22.2%) and PsA (AU$114,299,422; 20.3%). JIA accounted for AU$16,568,724 (2.9% of total savings). Table 3Total estimated savings within each indicationAdalimumab (from 2021‐Apr)Etanercept (from 2017‐Apr)Infliximab (from 2015‐Dec)Adalimumab + Etanercept + InfliximabEstimated saving%Estimated saving%Estimated saving%Estimated saving%RA$95,336,21948.8$205,903,02360.3$5,631,57522.0$306,870,81754.6AS$44,386,28622.7$66,177,79019.4$14,013,81655.0$124,577,89222.2PsA$46,913,21624.0$61,532,80918.0$5,853,39723.0$114,299,42220.3JIA$8,655,2894.5$7,913,4352.3n/a0.0$16,568,7242.9Total$195,291,010‐$341,527,057‐$25,498,788‐$562,316,855‐AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; n/a, not applicable; PsA, psoriatic arthritis; RA, rheumatoid arthritis. Total estimated savings within each indication AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; n/a, not applicable; PsA, psoriatic arthritis; RA, rheumatoid arthritis. Across all indications, etanercept contributed the largest share of savings, particularly for RA and PsA. Adalimumab also contributed substantially to savings in RA, AS, and PsA. No savings were observed for infliximab in JIA, as this indication is not subsidized under the PBS and therefore not captured in dispensing data (see Table S11 for detailed estimates of actual and hypothetical expenditure by indication). DISCUSSION Biologic therapies remain among the most expensive medicines subsidized through Australia's PBS, with TNF inhibitors representing a growing share of national pharmaceutical expenditure. Biosimilars, clinically equivalent but lower cost alternatives, have the potential to improve affordability while maintaining high standards of care. While international studies have documented cost savings from biosimilar adoption, 22 , 23 , 24 real‐world evaluations within Australia's unique PBS pricing framework remain limited. Leveraging national dispensing and pricing data from 2015 to 2025 across multiple indications and explicitly accounting for PBS pricing mechanisms, this study quantifies PBS cost savings attributable to adalimumab, etanercept, and infliximab biosimilars. Our findings extend prior market‐level analysis by estimating savings specifically for TNF inhibitor biosimilars within Australia's unique PBS formulary and pricing framework. 25 This demonstrates how regulated pricing mechanisms translate biosimilar entry into realized system‐level savings, with implications for equitable access to biologic therapies and healthcare resource allocation. Inclusion of adalimumab captures both its delayed biosimilar PBS listing and its substantial contribution to overall biologic expenditure. TNF inhibitor biosimilar listings generated ~AU$562 million in cumulative savings between 2015 and 2025, supporting more sustainable PBS expenditure. Etanercept contributed the largest absolute savings (~AU$341 million) due to earlier biosimilar PBS listing in April 2017 and rapid uptake. Infliximab biosimilars, first PBS‐listed in December 2015, delivered the highest relative saving (~35%), though absolute savings were smaller due to lower prescription volumes and prior price reductions. Adalimumab biosimilars produced more modest savings (~9%), largely reflecting delayed PBS listing in April 2021 (e.g., Amgevita, Hadlima). 26 These differences can be explained by Australia's structured PBS pricing policies: first biosimilar listing moves the reference biologic to the multi‐brand formulary (F2) with a mandatory price reduction, followed by successive price‐disclosure cycles. Smaller relative savings for adalimumab compared with infliximab and etanercept likely result from its later PBS listing combined with prior anniversary price reductions (5‐, 10‐, and 15‐year milestones), which lowered baseline prices before biosimilar competition. Together, these findings illustrate how the interaction between entry timing and statutory pricing rules determines the magnitude and trajectory of realized savings. Similar to the United States, 27 adalimumab illustrates the opportunity costs associated with delayed PBS listing. Although the Pharmaceutical Benefits Advisory Committee (PBAC) recommended listing in 2018, adalimumab biosimilars were added only in 2021, 26 meaning that price reductions occurred largely through statutory anniversary cuts rather than competitive mechanisms, limiting system‐level savings. This reduced exposure to competition‐driven price erosion highlights timely reimbursement decisions as a modifiable policy lever for maximizing biosimilar value. In the Australian context, our TNF inhibitor biosimilar savings estimates can be situated alongside findings from other similar analyses. Gleeson et al. estimated that if biosimilar versions of 10 different biologic medicines had been available and PBS‐listed in 2015–16, at least AU$367 million in annual PBS subsidies could have been saved. 28 Market‐level analysis by Hillen et al., which also investigated rituximab and trastuzumab biosimilars, reported that within 12 months of biosimilar entry, total expenditure for biologic reference products was reduced by 38.3%, with average unit prices declining by 30–40%. 25 Our findings for TNF inhibitors in inflammatory arthritis complement these studies. Savings trajectories vary substantially depending on molecule‐specific factors, including biosimilar entry timing, statutory pricing mechanisms, PD cycles, and the extent of biosimilar competition. Our findings also align with international evidence that biosimilar‐related savings are shaped by policy design and timing across therapeutic areas. Different policy approaches illustrate this further. In the United States, modest biosimilar uptake and limited price reductions under product‐specific reimbursement constrained savings, whereas alternative reimbursement approaches, such as bundled reimbursement, could have generated larger reductions. 29 In France, sequential price reductions followed biosimilar launches through centralized tariff setting combined with decentralized hospital negotiations, 30 while in Finland, reference product price declines were driven primarily by reimbursement policies rather than market competition alone. 31 In South Korea, rapid biosimilar uptake produced substantial savings (~US$82–114 million for infliximab over 6 years), largely attributable to policy‐driven price reductions. 32 Similarly, Ontario's TNF inhibitor experience highlights that the timing of biosimilar listing and structured reimbursement policies determine realized savings. 24 Collectively, these findings reinforce that early biosimilar entry combined with effective pricing and reimbursement design is critical for translating biosimilar availability into realized savings. Implications for biosimilar developers and healthcare systems While the cost savings estimated in this study reflect the downstream impact of biosimilar availability, realizing the full potential of biosimilar competition will require coordinated action across biosimilar developers, regulators, and healthcare systems. For biosimilar developers, recent initiatives signal a shift toward streamlined biosimilar approval pathways. In early 2026, the European Medicines Agency (EMA) published a reflection paper proposing that biosimilarity may be established based primarily on robust analytical comparability, in vitro functional characterization, and comparative pharmacokinetic studies, potentially reducing the requirement for large‐scale comparative efficacy studies when structure–function relationships are well understood. 33 The US Food and Drug Administration (FDA) has similarly indicated that comparative efficacy trials may be waived when analytical and pharmacokinetic evidence is sufficiently robust, with stated objectives of reducing development timelines and lowering costs. 34 Harmonization of these regulatory requirements across jurisdictions would further reduce development costs and accelerate global market entry. 35 These developments suggest several priorities for developers: investment in advanced analytical characterization, early generation of robust pharmacokinetic comparability data, and proactive engagement with regulators through pre‐submission scientific advice. Furthermore, generating high‐quality, real‐world evidence on clinical outcomes following biosimilar adoption would strengthen clinician and payer confidence and support formulary decision making. For example, Australia's Person Level Integrated Dataset Asset (PLIDA) has enabled national treatment persistence analysis following etanercept biosimilar introduction, demonstrating the value of linked administrative data in generating post‐market evidence. 10 From a healthcare system perspective, several strategies could accelerate biosimilar uptake and maximize savings. First, timely translation of regulatory approval into reimbursement listing is critical to minimize foregone savings, as illustrated by the delayed listing of adalimumab biosimilars in Australia following PBAC recommendation. 26 Second, prescribers' and patients' familiarity with biosimilars is a key determinant of uptake. 36 Structured clinician education programs and transparent communication about the evidence supporting biosimilar equivalence are essential to addressing hesitancy among prescribers and patients. Third, administrative measures such as streamlined authority requirements for biosimilar prescribing and hospital formulary policies favoring biosimilar procurement can further promote uptake. 37 Fourth, routine monitoring and public reporting of biosimilar uptake rates, pricing trajectories, and associated savings at the national level would provide the evidence base needed to inform ongoing policy refinement. Together, these coordinated actions represent practical levers to ensure that the cost savings demonstrated in this study continue to grow as additional high‐cost biologics face patent expiry in Australia and globally. Strengths and limitations This study leveraged comprehensive, nationwide PBS dispensing data spanning a decade (2015–2025), allowing robust estimation of biologic expenditure trajectories while capturing statutory anniversary price reductions and price‐disclosure mechanisms. Indication‐specific PBS item codes enabled precise stratification by RA, AS, PsA, and JIA without assumptions about redistribution of prescription volumes across conditions. Monthly prescription counts linked to time‐specific Approved Ex‐Manufacturer Prices improved temporal accuracy. The counterfactual model isolated biosimilar‐driven savings while retaining other statutory adjustments, avoiding overestimation of savings. Together, these features enhance transparency, reproducibility, and policy relevance. The methodology could also serve as a template for evaluating other high‐cost biologics (e.g., anticancer drugs or insulins) within the PBS. Several limitations should be acknowledged. First, the analysis relied on aggregated PBS data, preventing analysis of patient‐level treatment patterns, switching, or adherence. Second, biosimilar brands were analyzed at the molecule level, without modeling brand‐specific differences in pricing or uptake. Third, while generalizability to other countries is constrained by differences in reimbursement frameworks, the Australian PBS provides a useful example of how timely biosimilar listing and structured pricing policies can generate substantial system‐wide savings. Finally, as the analysis concludes in December 2025, additional savings, particularly for adalimumab, are likely to accrue beyond the study period. CONCLUSION The introduction of adalimumab, etanercept, and infliximab biosimilars has generated substantial cost savings within Australia's PBS, estimated at ~AU$562 million between 2015 and 2025. Savings were strongly influenced by the timing of biosimilar listing and the design of PBS pricing and reimbursement policies. Australia's framework, comprising mandatory price reductions at biosimilar PBS listing, formulary transitions, and price‐disclosure mechanisms, has been effective in reducing expenditure when biosimilars were introduced early. In contrast, delayed biosimilar listing, notably for adalimumab, limited potential savings despite high utilization. These findings highlight that timely PBS listing and effective pricing policy design are key, modifiable levers with direct implications for sustaining equitable access to biologic therapies and optimizing healthcare resource allocation. As more high‐cost biologics approach patent expiry, proactive implementation of these mechanisms will be critical to fully realize the economic and system‐level benefits of biosimilar competition in Australia and other health systems. FUNDING This study was supported by the University of Sydney Postgraduate Award received by Chin Hang Yiu. CONFLICTS OF INTEREST The authors declared no competing interests for this work. AUTHOR CONTRIBUTIONS C.H.Y, B.D.I, R.O.D, J.R, and C.Y.L wrote the manuscript; C.H.Y and C.Y.L designed the research; C.H.Y and B.D.I performed the research; C.H.Y analyzed the data. Supporting information Data S1. Acknowledgments Open access publishing facilitated by The University of Sydney, as part of the Wiley ‐ The University of Sydney agreement via the Council of Australasian University Librarians. References Associated Data Supplementary Materials Data S1.